Arcturus Therapeutics Holdings Inc. (ARCT)

↓ Download CSV

CIK 0001768224 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Arcturus Therapeutics Holdings Inc. reported revenue of $82.03M, down 46.1% from the prior year. The company ran a net loss, with a net margin of -80.2%. It held $271.15M in total assets against $57.16M in total liabilities.

Key ratios (FY2025)

-93.0%
Operating margin
-80.2%
Net margin
-30.7%
Return on equity
-46.1%
Revenue growth (YoY)
Metric (FY)202520242023202220212020201920182017
Revenue$82.03M$152.31M$166.80M$206.00M$12.36M$9.54M$20.79M$15.75M
Operating Income-$76.26M-$95.67M-$78.20M$12.18M-$202.85M-$71.52M-$25.51M-$21.81M
Net Income-$65.78M-$80.94M-$29.73M$9.35M-$203.67M-$72.15M-$25.99M-$21.79M
EPS (Diluted)$-2.40$-3.00$-1.12$0.35$-7.74
Total Assets$271.15M$344.07M$429.40M$450.39M$392.81M$476.46M$82.14M$44.20M
Total Liabilities$57.16M$103.09M$150.89M$180.07M$164.60M$79.90M$56.35M$30.56M
Shareholders' Equity$213.99M$240.98M$278.51M$270.31M$228.21M$396.55M$25.79M$13.64M$33.79M
Cash & Equivalents$230.91M$237.03M$292.00M$391.88M$370.49M$462.89M$71.35M$36.71M
Operating Cash Flow-$74.27M-$59.75M-$18.10M$31.99M-$135.04M-$42.86M-$6.45M-$20.76M
Capital Expenditures$230.0K$648.0K$2.90M$7.73M$3.41M$1.74M$818.0K$1.48M
Shares Outstanding28.41M27.00M26.83M26.55M26.37M26.19M15.14M10.72M